Insulin-like Growth Factor 2
EmergingIGF2 overexpression causes non-islet cell tumor hypoglycemia, an important differential when insulin/C-peptide don't explain low blood sugar.
IGF2 is a growth hormone active before birth. When certain tumors make too much of it, it can cause dangerously low blood sugar completely independent of insulin — an important thing for doctors to consider when insulin and C-peptide levels don't explain a patient's low blood sugar.
Insulin-like growth factor 2 (IGF2) is a growth-promoting hormone important in fetal development; its overexpression is implicated in both a genetic overgrowth syndrome and a distinct paraneoplastic hypoglycemia syndrome.
Overexpression is implicated in Beckwith-Wiedemann syndrome (an overgrowth disorder) and, notably, in non-islet cell tumor hypoglycemia — a paraneoplastic syndrome where certain tumors (often large mesenchymal or hepatic tumors) secrete excess IGF2, causing severe hypoglycemia independent of insulin.
Diagnosed via elevated IGF2:IGF1 ratio in the context of tumor-associated hypoglycemia, an important differential to consider when insulin and C-peptide (discussed earlier in this biomarker set) are both appropriately low in a hypoglycemic patient, ruling out insulinoma or factitious insulin use.
Treatment of non-islet cell tumor hypoglycemia focuses on removing or reducing the causative tumor when possible; glucose management (dextrose infusion, glucocorticoids, or growth hormone in refractory cases) addresses the hypoglycemia while definitive tumor treatment is pursued.
Connects directly to the insulin/C-peptide discussion earlier as a key alternative explanation for tumor-associated hypoglycemia.
- General endocrine oncology reference literature on non-islet cell tumor hypoglycemia and IGF2 overexpression.